JNJ - Here's Why Big Buyers Are Excited About This Cancer Immunotherapy Stock
Unlike many other mid-cap biotech companies, shares of Fate Therapeutics (NASDAQ: FATE) are almost entirely owned by institutional investors. Just what exactly does the company have in its pipeline that could entice so much interest from smart money?
As of now, over 90% of the company's 78 million shares outstanding are owned by institutional investors, representing a more than $2 billion bet that the company's pipeline candidates will be successful. As many biotech investors know, mid-cap biotech companies have significant risks associated with their clinical programs, especially when their leading candidates are only in phase 1, as the case with Fate Therapeutics.
IMAGE SOURCE: GETTY IMAGES